Lawmakers are considering a harmful Most Favored Nation (MFN) drug pricing proposal that would import foreign price controls into the U.S.—putting patient access and medical innovation at risk.

Many countries that rely on price controls use rigid formulas that limit or delay access to medicines, especially for seniors and people with disabilities. Americans have benefited from a better approach that allows unmatched access to lifesaving treatments that can save or extend our lives. MFN would turn its back on that progress, importing policies that delay or deny access and leave patients waiting when time matters most.

That access makes a real difference. American patients are 12 times more likely to receive the newest cancer medicines than patients in the U.K., per capita, and those medicines save lives. According to the American Cancer Society, the U.S. five‑year cancer survival rate reached 70% for patients diagnosed between 2015 and 2021. We shouldn’t risk that progress.

Instead of advancing proposals that undermine access and innovation, policymakers should focus on real solutions that help patients now—like reining in middlemen, holding 340B hospitals accountable and ending foreign free-riding. Other countries should pay their fair share for innovative medicines and if PBMs and hospitals get lower prices, those savings should go to patients–not profit margins.

TAKE ACTION NOW: Tell your lawmakers to reject MFN drug pricing and support policies that put American patients first.